Maple Syrup Urine Disease

Clinical and Therapeutic Considerations

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Maple syrup urine disease (MSUD) is an autosomal recessive disorder caused by a deficiency of the branched-chain α-ketoacid dehydrogenase complex (BCKDC). Patients with MSUD show variable degrees of enzyme deficiency leading to several distinct phenotypes. Classic MSUD patients exhibit pronounced branched-chain ketoacidosis, marked cerebral edema, and severe neurological impairments. Intermittent and intermediate forms of MSUD show lesser degrees of metabolic and clinical derangements. A thiamine-responsive form responding to the vitamin supplement and an E3-deficient form (see below) have also been described. Levels of residual BCKDC activity present in the patients guide regimens for dietary therapy.MSUD is genetically heterogeneous since the BCKDC is encoded by six different genetic loci. Using the tools of molecular biology, many mutations in all of these loci have been identified. A tight association of genetic lesions in the E2 locus with the thiamine-responsive MSUD phenotype was demonstrated. Restriction in the intake of branched-chain amino acids (BCAA) is the standard therapy to reduce the risk of metabolic decompensation. Liver transplantation has become an effective approach to control BCAA levels. Small-molecule inhibitors of the regulatory kinase may hold promise for reactivation of the BCKDC activity in some patients with low to intermediate enzyme activity. Naturally occurring and knockout animal models with classic and intermediate MSUD phenotypes, respectively, are available. Transplanted human amniotic epithelial cells significantly increased BCKDC enzyme activity in a mouse model of intermediate MSUD. The treatment resulted in prolonged animal survival, increased body weight and decreased circulating BCAA. Taken together, these advances will impact our approaches to developing effective therapies to mitigate the disease manifestations.

Original languageEnglish (US)
Title of host publicationRosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition
PublisherElsevier Inc.
Pages663-672
Number of pages10
ISBN (Print)9780124105294, 9780124105492
DOIs
StatePublished - Nov 13 2014

Fingerprint

Maple Syrup Urine Disease
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
Branched Chain Amino Acids
Therapeutics
Phenotype
Enzymes
Ketosis
Genetic Loci
Thiamine
Brain Edema
Vitamins
Liver Transplantation
Molecular Biology
Phosphotransferases
Animal Models
Epithelial Cells
Body Weight

Keywords

  • Branched-chain amino acids
  • Branched-chain ketoaciduria
  • Branched-chain α-ketoacid dehydrogenase complex
  • Human amniotic epithelial cell therapy
  • Maple syrup urine disease models
  • Maple syrup urine disease treatments
  • Neuropathology
  • Phenylbutyrate therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chuang, D. T., Max Wynn, R., Cox, R. P., & Chuang, J. L. (2014). Maple Syrup Urine Disease: Clinical and Therapeutic Considerations. In Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition (pp. 663-672). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-410529-4.00059-0

Maple Syrup Urine Disease : Clinical and Therapeutic Considerations. / Chuang, David T.; Max Wynn, R.; Cox, Rody P.; Chuang, Jacinta L.

Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., 2014. p. 663-672.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chuang, DT, Max Wynn, R, Cox, RP & Chuang, JL 2014, Maple Syrup Urine Disease: Clinical and Therapeutic Considerations. in Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., pp. 663-672. https://doi.org/10.1016/B978-0-12-410529-4.00059-0
Chuang DT, Max Wynn R, Cox RP, Chuang JL. Maple Syrup Urine Disease: Clinical and Therapeutic Considerations. In Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc. 2014. p. 663-672 https://doi.org/10.1016/B978-0-12-410529-4.00059-0
Chuang, David T. ; Max Wynn, R. ; Cox, Rody P. ; Chuang, Jacinta L. / Maple Syrup Urine Disease : Clinical and Therapeutic Considerations. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., 2014. pp. 663-672
@inbook{d4dd03f4d4874b9a84a3796666915764,
title = "Maple Syrup Urine Disease: Clinical and Therapeutic Considerations",
abstract = "Maple syrup urine disease (MSUD) is an autosomal recessive disorder caused by a deficiency of the branched-chain α-ketoacid dehydrogenase complex (BCKDC). Patients with MSUD show variable degrees of enzyme deficiency leading to several distinct phenotypes. Classic MSUD patients exhibit pronounced branched-chain ketoacidosis, marked cerebral edema, and severe neurological impairments. Intermittent and intermediate forms of MSUD show lesser degrees of metabolic and clinical derangements. A thiamine-responsive form responding to the vitamin supplement and an E3-deficient form (see below) have also been described. Levels of residual BCKDC activity present in the patients guide regimens for dietary therapy.MSUD is genetically heterogeneous since the BCKDC is encoded by six different genetic loci. Using the tools of molecular biology, many mutations in all of these loci have been identified. A tight association of genetic lesions in the E2 locus with the thiamine-responsive MSUD phenotype was demonstrated. Restriction in the intake of branched-chain amino acids (BCAA) is the standard therapy to reduce the risk of metabolic decompensation. Liver transplantation has become an effective approach to control BCAA levels. Small-molecule inhibitors of the regulatory kinase may hold promise for reactivation of the BCKDC activity in some patients with low to intermediate enzyme activity. Naturally occurring and knockout animal models with classic and intermediate MSUD phenotypes, respectively, are available. Transplanted human amniotic epithelial cells significantly increased BCKDC enzyme activity in a mouse model of intermediate MSUD. The treatment resulted in prolonged animal survival, increased body weight and decreased circulating BCAA. Taken together, these advances will impact our approaches to developing effective therapies to mitigate the disease manifestations.",
keywords = "Branched-chain amino acids, Branched-chain ketoaciduria, Branched-chain α-ketoacid dehydrogenase complex, Human amniotic epithelial cell therapy, Maple syrup urine disease models, Maple syrup urine disease treatments, Neuropathology, Phenylbutyrate therapy",
author = "Chuang, {David T.} and {Max Wynn}, R. and Cox, {Rody P.} and Chuang, {Jacinta L.}",
year = "2014",
month = "11",
day = "13",
doi = "10.1016/B978-0-12-410529-4.00059-0",
language = "English (US)",
isbn = "9780124105294",
pages = "663--672",
booktitle = "Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Maple Syrup Urine Disease

T2 - Clinical and Therapeutic Considerations

AU - Chuang, David T.

AU - Max Wynn, R.

AU - Cox, Rody P.

AU - Chuang, Jacinta L.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - Maple syrup urine disease (MSUD) is an autosomal recessive disorder caused by a deficiency of the branched-chain α-ketoacid dehydrogenase complex (BCKDC). Patients with MSUD show variable degrees of enzyme deficiency leading to several distinct phenotypes. Classic MSUD patients exhibit pronounced branched-chain ketoacidosis, marked cerebral edema, and severe neurological impairments. Intermittent and intermediate forms of MSUD show lesser degrees of metabolic and clinical derangements. A thiamine-responsive form responding to the vitamin supplement and an E3-deficient form (see below) have also been described. Levels of residual BCKDC activity present in the patients guide regimens for dietary therapy.MSUD is genetically heterogeneous since the BCKDC is encoded by six different genetic loci. Using the tools of molecular biology, many mutations in all of these loci have been identified. A tight association of genetic lesions in the E2 locus with the thiamine-responsive MSUD phenotype was demonstrated. Restriction in the intake of branched-chain amino acids (BCAA) is the standard therapy to reduce the risk of metabolic decompensation. Liver transplantation has become an effective approach to control BCAA levels. Small-molecule inhibitors of the regulatory kinase may hold promise for reactivation of the BCKDC activity in some patients with low to intermediate enzyme activity. Naturally occurring and knockout animal models with classic and intermediate MSUD phenotypes, respectively, are available. Transplanted human amniotic epithelial cells significantly increased BCKDC enzyme activity in a mouse model of intermediate MSUD. The treatment resulted in prolonged animal survival, increased body weight and decreased circulating BCAA. Taken together, these advances will impact our approaches to developing effective therapies to mitigate the disease manifestations.

AB - Maple syrup urine disease (MSUD) is an autosomal recessive disorder caused by a deficiency of the branched-chain α-ketoacid dehydrogenase complex (BCKDC). Patients with MSUD show variable degrees of enzyme deficiency leading to several distinct phenotypes. Classic MSUD patients exhibit pronounced branched-chain ketoacidosis, marked cerebral edema, and severe neurological impairments. Intermittent and intermediate forms of MSUD show lesser degrees of metabolic and clinical derangements. A thiamine-responsive form responding to the vitamin supplement and an E3-deficient form (see below) have also been described. Levels of residual BCKDC activity present in the patients guide regimens for dietary therapy.MSUD is genetically heterogeneous since the BCKDC is encoded by six different genetic loci. Using the tools of molecular biology, many mutations in all of these loci have been identified. A tight association of genetic lesions in the E2 locus with the thiamine-responsive MSUD phenotype was demonstrated. Restriction in the intake of branched-chain amino acids (BCAA) is the standard therapy to reduce the risk of metabolic decompensation. Liver transplantation has become an effective approach to control BCAA levels. Small-molecule inhibitors of the regulatory kinase may hold promise for reactivation of the BCKDC activity in some patients with low to intermediate enzyme activity. Naturally occurring and knockout animal models with classic and intermediate MSUD phenotypes, respectively, are available. Transplanted human amniotic epithelial cells significantly increased BCKDC enzyme activity in a mouse model of intermediate MSUD. The treatment resulted in prolonged animal survival, increased body weight and decreased circulating BCAA. Taken together, these advances will impact our approaches to developing effective therapies to mitigate the disease manifestations.

KW - Branched-chain amino acids

KW - Branched-chain ketoaciduria

KW - Branched-chain α-ketoacid dehydrogenase complex

KW - Human amniotic epithelial cell therapy

KW - Maple syrup urine disease models

KW - Maple syrup urine disease treatments

KW - Neuropathology

KW - Phenylbutyrate therapy

UR - http://www.scopus.com/inward/record.url?scp=84943231188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943231188&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-410529-4.00059-0

DO - 10.1016/B978-0-12-410529-4.00059-0

M3 - Chapter

SN - 9780124105294

SN - 9780124105492

SP - 663

EP - 672

BT - Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition

PB - Elsevier Inc.

ER -